ECSP055977A - Procedimiento para preparar la sal de 5-[(r)-2(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1h)-quinolin-2-ona, útil como un agonista de adrenoceptor - Google Patents

Procedimiento para preparar la sal de 5-[(r)-2(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1h)-quinolin-2-ona, útil como un agonista de adrenoceptor

Info

Publication number
ECSP055977A
ECSP055977A EC2005005977A ECSP055977A ECSP055977A EC SP055977 A ECSP055977 A EC SP055977A EC 2005005977 A EC2005005977 A EC 2005005977A EC SP055977 A ECSP055977 A EC SP055977A EC SP055977 A ECSP055977 A EC SP055977A
Authority
EC
Ecuador
Prior art keywords
hidroxi
indan
quinolin
salt
hydroxy
Prior art date
Application number
EC2005005977A
Other languages
English (en)
Inventor
Olivier Lohse
Caspar Vogel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927689&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP055977A publication Critical patent/ECSP055977A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se describe un procedimiento para preparar la sal de 5-[(R)-2-(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1H)-quinolin-2-ona. El procedimiento implica formar una sal de ácido de oxi-(1H)-quinolin-2-ona 5-[(R)-2-(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-substituida (V); y convertir la sal de ácido a una sal de 5-[(R)-2-(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1H)-quinolin-2-ona (VI) sin aislar la base libre de 5-[(R)-2-(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1H)-quinolin-2-ona. Fórmula (A); (V): R= un grupo protector, (VI): R = H.
EC2005005977A 2003-02-28 2005-08-24 Procedimiento para preparar la sal de 5-[(r)-2(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1h)-quinolin-2-ona, útil como un agonista de adrenoceptor ECSP055977A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45094503P 2003-02-28 2003-02-28

Publications (1)

Publication Number Publication Date
ECSP055977A true ECSP055977A (es) 2006-01-16

Family

ID=32927689

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005977A ECSP055977A (es) 2003-02-28 2005-08-24 Procedimiento para preparar la sal de 5-[(r)-2(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1h)-quinolin-2-ona, útil como un agonista de adrenoceptor

Country Status (30)

Country Link
US (1) US7534890B2 (es)
EP (1) EP1599450B1 (es)
JP (1) JP4802089B2 (es)
KR (1) KR101076929B1 (es)
CN (1) CN100363349C (es)
AR (1) AR043406A1 (es)
AT (1) ATE434609T1 (es)
AU (1) AU2004215647B2 (es)
BR (1) BRPI0407904B1 (es)
CA (1) CA2517033C (es)
CL (1) CL2004000381A1 (es)
CY (1) CY1109442T1 (es)
DE (1) DE602004021675D1 (es)
DK (1) DK1599450T3 (es)
EC (1) ECSP055977A (es)
ES (1) ES2326974T3 (es)
HK (1) HK1086255A1 (es)
IL (1) IL170138A (es)
MX (1) MXPA05009156A (es)
MY (1) MY142491A (es)
NO (1) NO331985B1 (es)
NZ (1) NZ541727A (es)
PE (1) PE20040956A1 (es)
PL (1) PL213932B1 (es)
PT (1) PT1599450E (es)
RU (1) RU2332405C2 (es)
SI (1) SI1599450T1 (es)
TW (1) TWI324150B (es)
WO (1) WO2004076422A1 (es)
ZA (1) ZA200506060B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324151B (en) * 2003-04-02 2010-05-01 Novartis Ag Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones
WO2004087142A1 (en) * 2003-04-04 2004-10-14 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
CA2654801C (en) * 2006-06-30 2014-08-19 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
CA2679059A1 (en) 2007-02-28 2008-09-04 Cipla Limited Process for preparing isomers of carmoterol
US8877930B2 (en) 2009-11-04 2014-11-04 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
WO2011109276A1 (en) 2010-03-01 2011-09-09 Massachussets Institute Of Technology Epoxidation catalysts
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
WO2014008639A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 制备茚达特罗的方法
WO2014008640A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
EP3848354B1 (en) 2012-09-21 2022-07-27 Crystal Pharma, S.A.U. Process for the preparation of indacaterol and intermediates thereof
WO2014044288A1 (en) * 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
ES2626829T3 (es) * 2013-03-27 2017-07-26 Laboratorios Lesvi, S.L. Procedimiento para la fabricación de (R)-5[2-(5,6-dietil-indan-2-ilamino)-1-hidroxietil]-8-hidroxi-(1H)-quinolin-2-ona
PL3092217T3 (pl) 2014-01-09 2020-11-16 Davuluri, Ramamohan Rao Nowy sposób wytwarzania indakaterolu lub jego farmaceutycznie dopuszczalnych soli
WO2016027283A2 (en) 2014-08-22 2016-02-25 Reddy G Pratap A process for preparing indacaterol and salts thereof
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
WO2016161956A1 (zh) * 2015-04-09 2016-10-13 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
US20190185461A1 (en) * 2015-07-21 2019-06-20 Sichuan Haisco Pharmaceutical Co., Ltd. Benzocyclic derivative having b2-receptor agonist activity and m3-receptor antagonist activity and medical use thereof
WO2017055506A1 (en) 2015-09-29 2017-04-06 Laboratorios Lesvi, S.L. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl] -8-hydroxy-1h-quinolin-2-one l-tartrate
CN107021921A (zh) * 2016-02-02 2017-08-08 常州爱诺新睿医药技术有限公司 一种茚达特罗中间体的盐及其制备方法
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN108101841B (zh) * 2016-11-24 2021-04-06 江苏恒瑞医药股份有限公司 一种制备茚达特罗或其盐的方法
CN108264483A (zh) * 2016-12-31 2018-07-10 天津金耀集团有限公司 一种马来酸茚达特罗的制备方法
CN109516974B (zh) * 2017-09-19 2022-05-27 南京圣和药业股份有限公司 取代嘧啶类pi3k抑制剂的制备方法
EP3735406B1 (en) 2018-01-02 2022-05-11 Deva Holding Anonim Sirketi A process for preparation of 5-(2-(substituted-amino)-1-hydroxyethyl)-8-(substituted-oxy) quinolin-2(1h)-one
CN109721534B (zh) * 2018-09-25 2022-05-20 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN109988111A (zh) * 2019-05-06 2019-07-09 淮北师范大学 一种马来酸茚达特罗的杂质及其合成方法
CN110128339B (zh) * 2019-05-31 2022-03-08 苏州芝宇生物科技有限公司 一种茚达特罗及其盐衍生物的合成方法和合成用中间体
CN113731406B (zh) * 2021-10-12 2023-07-28 南京工业大学 一种提高钯碳活性加氢脱除保护基的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR101076929B1 (ko) 2011-10-26
JP2006519206A (ja) 2006-08-24
NZ541727A (en) 2008-07-31
JP4802089B2 (ja) 2011-10-26
PT1599450E (pt) 2009-08-31
CL2004000381A1 (es) 2005-01-14
HK1086255A1 (en) 2006-09-15
US7534890B2 (en) 2009-05-19
MY142491A (en) 2010-11-30
BRPI0407904A (pt) 2006-02-14
CN100363349C (zh) 2008-01-23
BRPI0407904B1 (pt) 2016-09-20
DK1599450T3 (da) 2009-10-05
CN1753874A (zh) 2006-03-29
PE20040956A1 (es) 2005-01-20
CA2517033C (en) 2011-11-15
US20060252794A1 (en) 2006-11-09
AU2004215647B2 (en) 2006-12-21
ES2326974T3 (es) 2009-10-22
EP1599450A1 (en) 2005-11-30
DE602004021675D1 (de) 2009-08-06
KR20050105258A (ko) 2005-11-03
IL170138A (en) 2011-09-27
TWI324150B (en) 2010-05-01
CA2517033A1 (en) 2004-09-10
CY1109442T1 (el) 2014-08-13
RU2005129547A (ru) 2007-04-10
NO331985B1 (no) 2012-05-21
RU2332405C2 (ru) 2008-08-27
NO20054452L (no) 2005-11-28
AR043406A1 (es) 2005-07-27
WO2004076422A1 (en) 2004-09-10
SI1599450T1 (sl) 2009-12-31
NO20054452D0 (no) 2005-09-26
PL213932B1 (pl) 2013-05-31
TW200505864A (en) 2005-02-16
MXPA05009156A (es) 2005-10-20
PL378358A1 (pl) 2006-03-20
EP1599450B1 (en) 2009-06-24
AU2004215647A1 (en) 2004-09-10
ZA200506060B (en) 2006-07-26
ATE434609T1 (de) 2009-07-15

Similar Documents

Publication Publication Date Title
ECSP055977A (es) Procedimiento para preparar la sal de 5-[(r)-2(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1h)-quinolin-2-ona, útil como un agonista de adrenoceptor
MA46452B1 (fr) Composés de benzo[b]thiophéne en tant qu'agonistes de sting
RS53398B (en) PROCEDURE FOR OBTAINING AMINO CROTONYL UNITS
BR0308967A (pt) Derivados de quinolina e isoquinolina, um processo para a sua preparação e sua aplicação como inibidores de inflamação
AR064833A1 (es) Un procedimiento para la preparacion de vildagliptin
HRP20120129T1 (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
CO5700779A2 (es) Un proceso para la preparación de oxi-(1h)-quinolin-2-onas 5-(haloacetil)-8-sustituidas
RS51341B (en) INTERMEDIATE COMPOUNDS FOR THE TRANS-5-CHLOR-2-METHYL-2,3A, 12B-TETRAHYDRO-1H-DIBENZE [2,3; 6,7] OXEPINO [4,5-C] Pyrrole
EA200870321A1 (ru) Способ получения 4-оксохинолинового соединения
BRPI0411268A (pt) processo para a preparação de um composto 3-aril butil-amina substituìdo
BRPI0511433A (pt) derivados de quinolina substituìda como inibidores de cinesina mitótica
AR051373A1 (es) Procedimiento para la preparacion de analogos aciclicos de nucleotidos de fosfonatos
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
AR047523A1 (es) Procedimiento para la preparacion de 1-(2s,3s)-2-bencidril-n-(5-terc-butil-2-metoxibencil)quinuclidin-3-amina
IL187640A0 (en) Method for preparing clopidogrel and intermediates used therein
AR057555A1 (es) Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
EA201290228A1 (ru) Соединение бензазепина
BRPI0806411B8 (pt) processo para a preparação de um composto e compostos
RS51079B (sr) Novi naftalenski derivati, postupak njihove proizvodnje i farmaceutske smeše koje ih sadrže
EA200701962A1 (ru) Аддитивные соли толперизона, способ их получения и их применение
IL157495A0 (en) Method for the production of d-panthothenic acid and/or salts thereof as adjunct for animal feedstuffs
EA201300100A3 (ru) Способ ферментативного синтеза(7s)-3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-карбоновой кислоты или ее сложных эфиров, и применение для синтеза ивабрадина и его соли
BR0116853A (pt) Processo para a preparação de um composto, e, composto.
EA201400563A1 (ru) Способ получения хинолинкарбоновой кислоты
EA201170458A1 (ru) СПОСОБ ПОЛУЧЕНИЯ 1,6:2,3-ДИАНГИДРО-β-D-МАННОПИРАНОЗЫ